Loading
c-Met overexpression is a stain, not a gene change: strong (3+) membrane staining in at least half of tumour cells. It selects telisotuzumab vedotin, an antibody-drug conjugate, in previously treated non-squamous lung cancer.
The VENTANA MET (SP44) RxDx Assay scores c-Met protein on tumour cell membranes and cytoplasm; the telisotuzumab vedotin (Emrelis, May 2025) label defines high c-Met overexpression as 50 percent or more of tumour cells with strong (3+) staining, as determined by an FDA-approved test, in locally advanced or metastatic non-squamous NSCLC after prior systemic therapy (LUMINOSITY). About a quarter of non-squamous, EGFR wild-type lung cancers meet the bar. Overexpression can occur without amplification or exon 14 skipping and the three readouts are scored separately.
In plain words · A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.
If the SP44 stain shows strong c-Met in at least half of your non-squamous lung cancer cells, telisotuzumab vedotin is on label after a first treatment has stopped working. This is a protein stain, so a sequencing report that says nothing about MET does not answer the question; ask whether the stain was done.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
50 percent or more of tumour cells showing strong (3+) membranous and/or cytoplasmic c-Met staining on the VENTANA MET (SP44) RxDx Assay.
“MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+)”
FDA: List of FDA-Authorized Companion Diagnostic Devices| Threshold | Drug | Cancer | Regulator | Source |
|---|---|---|---|---|
| >= 50% of tumour cells with strong (3+) staining | Telisotuzumab vedotin | Non-small-cell lung cancer | FDA | label |
| Device | Maker | Indication and sample | Drug | PMA / 510(k) |
|---|---|---|---|---|
| VENTANA MET (SP44) RxDx Assay | Ventana Medical Systems (Roche Tissue Diagnostics) | Non-Small Cell Lung Cancer (NSCLC) - Tissue | Telisotuzumab vedotin | P240037 (05/14/2025) |
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares MET exon 14 skipping mutation, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, Telisotuzumab vedotin, MET.
Shares MET exon 14 skipping mutation, MET amplification (gene copy number), MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, MET.
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
Shares Immunohistochemistry (IHC) and the tag biomarker.
Shares MET amplification (gene copy number), MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, Telisotuzumab vedotin, MET.
Shares Immunohistochemistry (IHC), Non-small-cell lung cancer and the tag biomarker.
Shares Immunohistochemistry (IHC), Non-small-cell lung cancer and the tag biomarker.
Shares Immunohistochemistry (IHC) and the tag biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/